You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Bolus Articles
Popular Bolus Articles
Highly Recommended Bolus Articles
Send a link to this page to your friends and colleagues.
CeQur SA, a Swiss company that develops insulin delivery devices, has received approval to market its PaQ® insulin delivery device in Europe.
The PaQ is a wearable device that delivers three days' worth of basal, as well as on-demand bolus, insulin for people with type 2 diabetes. The device combines a disposable insulin-infuser reservoir with a reusable insulin monitor to function.
CeQur spokesmen estimate that more than 30 million in the 27-nation European Union take multiple daily injections of insulin to manage their diabetes, including a substantial number of type 2s. Because tight control of blood glucose levels is essential to avoiding long-term complications from diabetes, adhering closely to a dosing schedule is important.
However, the company estimates that half of all patients taking insulin intentionally skip doses if they find giving themselves an injection to be embarrassing, inconvenient, painful, or disruptive. CeQur believes that continuous insulin-infusion technology, discretely attached under clothing, will do much to improve drug adherence.
Established in 2008 in Switzerland, CeQur also has a production facility in Marlborough, Massachusetts. Even though it has a U.S. location, the company has not said when it might ask for FDA approval to sell the PaQ in the American market.
CeQur's website is located at www.cequrcorp.com.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.